We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

16 Nov 2026 - 19 Nov 2026
08 Dec 2026 - 10 Dec 2026

Intranasal Spray to Prevent Illnesses from Respiratory Viruses

By HospiMedica International staff writers
Posted on 05 Feb 2026

Respiratory viruses such as influenza and COVID-19 hospitalize more than one million people in the U. More...

S. each year, with many infections spreading through close contact in households, schools, and workplaces. People regularly exposed to young children or crowded environments face an especially high risk. Current preventive strategies largely focus on virus-specific vaccines, leaving gaps when multiple pathogens circulate. A new clinical trial is now testing a preventive nasal therapy designed to strengthen the body’s frontline immune defenses before infection takes hold.

Led by the University of Maryland School of Medicine (Baltimore, MD, USA), in collaboration with industry partner ENA Respiratory (Melbourne, VC, Australia), the randomized double-blind Phase 2 trial will enroll 1,100 healthy adults aged 18 to 45 who are at increased risk of respiratory infections. Participants will receive either the experimental intranasal spray or a placebo to evaluate safety, immune activation, and illness prevention.

The investigational therapy is a non-vaccine, virus-agnostic intranasal spray designed for weekly use during cold and flu season. It works as a TLR2/6 agonist, priming the immune system’s first line of defense at the nasal mucosa. By acting at the initial site of viral entry and replication, the spray aims to accelerate pathogen clearance before infection can become established.

This Phase 2 trial will assess whether the therapy reduces the likelihood or severity of respiratory illness compared with placebo. Researchers will monitor immune responses and clinical outcomes throughout the respiratory virus season. While results are pending, the study builds on earlier evidence suggesting that strengthening mucosal immunity could protect against multiple respiratory pathogens. The trial is designed to provide clear safety and efficacy data in a real-world exposure setting.

If successful, the approach could complement existing vaccines by offering broad, early protection against diverse respiratory viruses. Such a strategy may be especially valuable for people with frequent exposure risks or underlying conditions that increase complication rates. Researchers also see potential for this immune-priming approach to improve preparedness for future respiratory outbreaks. Further trials could expand testing to older adults and higher-risk populations.

“This study represents a new approach to reducing illness from respiratory infections,” said Professor Justin Ortiz, MD, principal investigator of the trial. “Instead of targeting a single virus, this strategy strengthens the body’s early immune defenses, which may help mitigate disease caused by multiple respiratory pathogens.”

Related Links:
University of Maryland School of Medicine
ENA Respiratory


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Rapid Sepsis Test
SeptiCyte RAPID
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image Credit: Adobe Stock

Lung Ultrasound Predicts Progression of Interstitial Lung Abnormalities in Rheumatoid Arthritis

Interstitial lung abnormalities are a pulmonary concern in patients with rheumatoid arthritis, requiring monitoring to detect disease progression. However, tracking these changes often involves repeated... Read more

Point of Care

view channel
Image: Fluorescence image of water-acetone mixture condensation. (Photo courtesy of Jingcheng Ma/Interfacial Thermofluids Laboratory)

New Breath Condensate Testing Approach Enhances Reliability for COPD Monitoring

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that can increasingly impair breathing over time. Diagnosis and monitoring may be burdensome because patients often require... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.